Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy

Affiliation auteurs!!!! Error affiliation !!!!
TitreReduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy
Type de publicationJournal Article
Year of Publication2017
AuteursGauthier J., Castagna L., Garnier F., Guillaume T., Socie G., Maury S., Maillard N., Tabrizi R., Marchand T., Malfuson J., Gac A., Gyan E., Mercier M., Beguin Y., Delage J., Turlure P., Marcais A., Nguyen S., Dulery R., Bay J., huynh A., Daguindau E., Cornillon J., Regny C., Michallet M., R. de latour P, Yakoub-Agha I., Blaise D.
JournalBONE MARROW TRANSPLANTATION
Volume52
Pagination689-696
Date PublishedMAY
Type of ArticleArticle
ISSN0268-3369
Résumé

{Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from HAPLO, MMUD or CB. Ninety-eight patients were included. Median follow-up was 31 months for the whole cohort. All patients in the HAPLO group (N = 34) received a T-cell replete allo-SCT after a NMA (FLU-CY-TBI
DOI10.1038/bmt.2016.349